Inflammatory, Serological and Vascular Determinants of Cardiovascular Disease in Systemic Lupus Erythematosus Patients

Overview

Journal Int J Mol Sci

Publisher MDPI

Specialties Biochemistry
Chemistry
Molecular Biology

Date 2019 May 5

PMID 31052336

Citations 17

Authors

Valentina Mercurio

Antonio Lobasso

Letizia Barbieri

Paolo Parrella

Deasy Ciervo

Bianca Liccardo

Domenico Bonaduce

Carlo G Tocchetti

Amato De Paulis

Francesca W Rossi

Affiliations

Soon will be listed here.

Abstract

Background And Aim: Systemic lupus erythematosus (SLE) is associated with increased risk of cardiovascular disease (CVD). Among many mechanisms, accelerated atherosclerosis, endothelial dysfunction, and hypercoagulability play a main role. Here, we investigate whether inflammatory, serological and clinical markers of SLE determine and correlate with arterial stiffness in SLE patients.

Materials And Methods: Routine blood samples, inflammatory mediators, specific antibodies, and 24 h proteinuria were measured in 43 SLE patients and 43 age and sex-matched controls using routine laboratory assays. We also assessed arterial stiffness by measuring radial artery applanation tonometry-derived augmentation index (AI), normalized AI (AIx@75), aortic pulse pressure, central systolic, diastolic and peripheral blood pressure.

Results: SLE patients showed a significantly greater arterial stiffness vs. controls, as demonstrated by the significantly higher AIx@75 and aortic pulse pressure. Interestingly, regression analysis showed that age, systolic pulse pressure, inflammatory markers (erythrocyte sedimentation rate and C-reactive protein), daily dose of glucocorticoids, and cumulative organ damage positively correlated with arterial stiffness.

Conclusions: SLE patients show increased arterial stiffness which correlates with markers of inflammation, that is involved in early alterations in arterial walls. Applanation tonometry can be used to screen SLE patients for subclinical vascular damage to implement prevention strategies for CVD.

Citing Articles

Artificial intelligence-based cardiovascular/stroke risk stratification in women affected by autoimmune disorders: a narrative survey.

Tiwari E, Shrimankar D, Maindarkar M, Bhagawati M, Kaur J, Singh I Rheumatol Int. 2025; 45(1):14.

PMID: 39745536 DOI: 10.1007/s00296-024-05756-5.

Comparison of Metabolic Syndrome, Autoimmune and Viral Distinctive Inflammatory Related Conditions as Affected by Body Mass Index.

Chero-Sandoval L, Martinez-Urbistondo M, Cuevas-Sierra A, Higuera-Gomez A, Martin-Domenech E, Castejon R J Clin Med. 2024; 13(21).

PMID: 39518437 PMC: 11547109. DOI: 10.3390/jcm13216298.

Phylloquinone improves endothelial function, inhibits cellular senescence, and vascular inflammation.

Kieronska-Rudek A, Kij A, Bar A, Kurpinska A, Mohaissen T, Grosicki M Geroscience. 2024; 46(5):4909-4935.

PMID: 38980631 PMC: 11336140. DOI: 10.1007/s11357-024-01225-w.

Assessment of Arterial Stiffness and Biochemical Markers in Systemic Lupus Erythematosus in the Diagnosis of Subclinical Atherosclerosis.

Blachut D, Przywara-Chowaniec B, Mazurkiewicz M, Tomasik A J Pers Med. 2024; 14(3).

PMID: 38541031 PMC: 10971100. DOI: 10.3390/jpm14030289.

Fourier transform infrared spectroscopy and machine learning for Porphyromonas gingivalis detection in oral bacteria.

Kaneda T, Watanabe M, Honda H, Yamamoto M, Inagaki T, Hironaka S Anal Sci. 2024; 40(4):691-699.

PMID: 38374487 DOI: 10.1007/s44211-023-00501-7.

References

Bulkley B, Roberts W . The heart in systemic lupus erythematosus and the changes induced in it by corticosteroid therapy. A study of 36 necropsy patients. Am J Med. 1975; 58(2):243-64. DOI: 10.1016/0002-9343(75)90575-6. View

Rahman P, Aguero S, Gladman D, Hallett D, Urowitz M . Vascular events in hypertensive patients with systemic lupus erythematosus. Lupus. 2001; 9(9):672-5. DOI: 10.1191/096120300669204787. View

Selzer F, Sutton-Tyrrell K, Fitzgerald S, Tracy R, Kuller L, Manzi S . Vascular stiffness in women with systemic lupus erythematosus. Hypertension. 2001; 37(4):1075-82. DOI: 10.1161/01.hyp.37.4.1075. View

Borba E, Bonfa E . Longterm beneficial effect of chloroquine diphosphate on lipoprotein profile in lupus patients with and without steroid therapy. J Rheumatol. 2001; 28(4):780-5. View

Gladman D, Ibanez D, Urowitz M . Systemic lupus erythematosus disease activity index 2000. J Rheumatol. 2002; 29(2):288-91. View

Urowitz M, Bookman A, Koehler B, Gordon D, Smythe H, OGRYZLO M . The bimodal mortality pattern of systemic lupus erythematosus. Am J Med. 1976; 60(2):221-5. DOI: 10.1016/0002-9343(76)90431-9. View

Manger K, Kusus M, Forster C, Ropers D, Daniel W, Kalden J . Factors associated with coronary artery calcification in young female patients with SLE. Ann Rheum Dis. 2003; 62(9):846-50. PMC: 1754656. DOI: 10.1136/ard.62.9.846. View

Rajagopalan S, Somers E, Brook R, Kehrer C, Pfenninger D, Lewis E . Endothelial cell apoptosis in systemic lupus erythematosus: a common pathway for abnormal vascular function and thrombosis propensity. Blood. 2004; 103(10):3677-83. DOI: 10.1182/blood-2003-09-3198. View

Verma S, Kuliszewski M, Li S, Szmitko P, Zucco L, Wang C . C-reactive protein attenuates endothelial progenitor cell survival, differentiation, and function: further evidence of a mechanistic link between C-reactive protein and cardiovascular disease. Circulation. 2004; 109(17):2058-67. DOI: 10.1161/01.CIR.0000127577.63323.24. View

10.

MacGregor A, Dhillon V, Binder A, Forte C, Knight B, Betteridge D . Fasting lipids and anticardiolipin antibodies as risk factors for vascular disease in systemic lupus erythematosus. Ann Rheum Dis. 1992; 51(2):152-5. PMC: 1005648. DOI: 10.1136/ard.51.2.152. View

11.

Haque S, Bruce I . Therapy insight: systemic lupus erythematosus as a risk factor for cardiovascular disease. Nat Clin Pract Cardiovasc Med. 2005; 2(8):423-30. DOI: 10.1038/ncpcardio0270. View

12.

Pepys M, Hirschfield G, Tennent G, Gallimore J, Kahan M, Bellotti V . Targeting C-reactive protein for the treatment of cardiovascular disease. Nature. 2006; 440(7088):1217-21. DOI: 10.1038/nature04672. View

13.

Bjarnegrad N, Bengtsson C, Brodszki J, Sturfelt G, Nived O, Lanne T . Increased aortic pulse wave velocity in middle aged women with systemic lupus erythematosus. Lupus. 2006; 15(10):644-50. DOI: 10.1177/0961203306071402. View

14.

Weber T, Auer J, Lamm G, ORourke M, Eber B . Arterial stiffness, central blood pressures, and wave reflections in cardiomyopathy-implications for risk stratification. J Card Fail. 2007; 13(5):353-9. DOI: 10.1016/j.cardfail.2007.02.008. View

15.

Denny M, Thacker S, Mehta H, Somers E, Dodick T, Barrat F . Interferon-alpha promotes abnormal vasculogenesis in lupus: a potential pathway for premature atherosclerosis. Blood. 2007; 110(8):2907-15. PMC: 2018671. DOI: 10.1182/blood-2007-05-089086. View

16.

Soubrier M, Mathieu S, Dubost J . Atheroma and systemic lupus erythematosus. Joint Bone Spine. 2007; 74(6):566-70. DOI: 10.1016/j.jbspin.2007.04.006. View

17.

Salmon J, Roman M . Subclinical atherosclerosis in rheumatoid arthritis and systemic lupus erythematosus. Am J Med. 2008; 121(10 Suppl 1):S3-8. PMC: 2581713. DOI: 10.1016/j.amjmed.2008.06.010. View

18.

Shang Q, Tam L, Li E, Yip G, Yu C . Increased arterial stiffness correlated with disease activity in systemic lupus erythematosus. Lupus. 2008; 17(12):1096-102. DOI: 10.1177/0961203308092160. View

19.

Safar M . Pulse pressure, arterial stiffness and wave reflections (augmentation index) as cardiovascular risk factors in hypertension. Ther Adv Cardiovasc Dis. 2009; 2(1):13-24. DOI: 10.1177/1753944707086652. View

20.

Gasparyan A, Stavropoulos-Kalinoglou A, Mikhailidis D, Toms T, Douglas K, Kitas G . The rationale for comparative studies of accelerated atherosclerosis in rheumatic diseases. Curr Vasc Pharmacol. 2009; 8(4):437-49. DOI: 10.2174/157016110791330852. View